This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Carl Dahlöf, MD, PhD; Karl Ekbom, MD, PhD; Lennart Persson, MD, PhD

Arch Neurol. 1994;51(12):1256-1261.

Abstract
This article reviews, from the practitioner's point of view, more than 1 year of clinical experience of the use of subcutaneously administered sumatriptan succinate in the shortterm treatment of migraine and cluster headache with regard to advantages and disadvantages of the drug. In accordance with the results of clinical trials, subcutaneous sumatriptan, also in the practitioner's hands, was found to relieve migraine headaches and all other symptoms associated with migraine in most patients and within a reasonable period. Adverse events, however, are common and were perceived by about 70% of the patients. The most common adverse events were pressure/stiffness in the neck and throat (32%), general tiredness (22%), pressure/tightness over the chest (21%), injection site reactions (16%), and tingling sensations in the head and arms (14%). Headache recurrence within 24 hours is a clinical problem not only for the patient but also for the prescribing physician. About every second (53%) migraineur using subcutaneous sumatriptan reports headache recurrence. Headache recurrence appears to be effectively treated by a second injection. Pending valid information about effects, adverse events, headache recurrence, and how to handle the autoinjector, the compliance and tolerability of subcutaneous sumatriptan appear to be most satisfactory among eligible patients with migraine.

Author Affiliations
From the Gothenburg Migraine Clinic, Sodala Huset, Uppg D, Gothenburg, Sweden (Dr Dahlöf); the Department of Neurology, Söder Hospital, Stockholm, Sweden (Dr Ekbom); and the Department of Neurology, Sahlgren's Hospital, Gothenburg, Sweden (Dr Persson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of oral dexamethasone versus placebo after ED treatment of migraine with phenothiazines on the rate of recurrent headache: a randomised controlled trial
Kelly et al.
Emerg. Med. J. 2008;25:26-29.
ABSTRACT | FULL TEXT  

Sumatriptan (5-HT1B/1D-agonist) Causes a Transient Allodynia
Linde et al.
Cephalalgia 2004;24:1057-1066.
ABSTRACT | FULL TEXT  

Open-Labeled Long-Term Study of the Efficacy, Safety, and Tolerability of Subcutaneous Sumatriptan in Acute Migraine Treatment
Gobel et al.
Cephalalgia 1999;19:676-683.
ABSTRACT